home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408e.zip
/
M9480868.TXT
< prev
next >
Wrap
Text File
|
1994-09-05
|
3KB
|
41 lines
Document 0868
DOCN M9480868
TI Radiometric susceptibility testing of Mycobacterium tuberculosis against
second-line drugs.
DT 9410
AU Salfinger M; Gross W; Kornblum J; Laszlo A; Pfyffer G; Roberts G;
Siddiqi S; NY State Dept. of Health, Albany.
SO Abstr Gen Meet Am Soc Microbiol. 1994;94:197 (abstract no. U-138).
Unique Identifier : AIDSLINE ASM94/94313077
AB AIDS epidemic, deterioration of the public health infrastructure and
inadequate training of health care providers are some factors
contributing to the increase of tuberculosis (TB), especially
multidrug-resistant TB. In vitro drug susceptibility testing is now
required for all TB patients. Since faster turnaround times in the TB
laboratory are necessary, we compared the radiometric technique with the
conventional Middlebrook 7H10 agar method for susceptibility to
second-line drugs in a 3 phase study. In phase I, 10 susceptible M.
tuberculosis strains were tested in the BACTEC system against the
following drugs and concentration (mcg/ml): amakicin (AN, 1.0, 2.0,
4.0), capreomycin (CM, 1.25, 2.5, 5.0), ciprofloxacin (CIP, 0.5, 1.0,
2.0), clofazimine (CLO, 0.25, 0.5, 1.0), cycloserine (CS, 50, 60, 70),
ethionamide (ETA, 1.25, 2.5, 5.0), kanamycin (KM, 1.25, 2.5, 5.0),
ofloxacin (OFL, 0.5, 1.0, 2.0, 4.0). In phase II, specially selected 20
isolates with some strains resistant to each drug were tested. Drug
concentrations were adjusted based on the results in Phase I. CIP was
dropped and rifabutin (RBT, 0.5, 1.0, 2.0) was included. The following
preliminary critical concentrations (mcg/ml) for radiometric method were
established: AN 1.0, CM 2.5, CLO 0.25, CS 100.0, ETA 1.25, KM 2.5, OFL
2.0, and RBT 1.0. Final recommendations will be made after finishing
testing 30-50 recent clinical isolates in phase III.
DE Antibiotics/*TOXICITY AIDS-Related Opportunistic Infections/DRUG
THERAPY Capreomycin Comparative Study Drug Resistance, Microbial
Human Microbial Sensitivity Tests/*METHODS Mycobacterium
tuberculosis/*DRUG EFFECTS/GROWTH & DEVELOPMENT/ ISOLATION & PURIF
Species Specificity Tuberculosis, Pulmonary/COMPLICATIONS/DRUG THERAPY
MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).